GRM3 and early-onset autosomal dominant Alzheimer disease: LY2389575 established a key role of mGluR3 in neuroprotection against β-amyloid induced toxicity (Caraci et al., 2010; Sheffler et al., 2011a), suggesting that pharmacological activation of mGluR3 with PAMs may be a possible therapeutic strategy in Alzheimer’s disease.